Click on the PubMed logo to access the abstract

Study design¹

• This prospective 1-year, multicenter, open-label study evaluated whether fixed starting doses of EXJADE (based on iron intake from ongoing blood transfusions), followed by dose titration according to serum ferritin trends and safety markers, could provide effective iron chelation in patients with a variety of transfusion-dependent anemias (N=1744)

Patient profile¹

• Patients had transfusion overload, defined as:
  • Serum ferritin ≥1000 μg/L OR
  • Serum ferritin <1000 μg/L, a history of multiple transfusions (more than 20 transfusions or 100 mL/kg red blood cells, and R2 magnetic resonance imaging-confirmed LIC of ≥2 mg Fe/g dry weight
• Of the 1744 enrolled patients, 341 had MDS
• Median baseline serum ferritin was 2730 μg/L for the overall population; baseline levels in chelation-naïve and previously chelated patients were 2716 and 2764 μg/L, respectively
• Mean ALT at baseline was 59.7 at baseline

Results¹

• EXJADE reduced median serum ferritin by 35% in chelation-naïve patients (2716-1754 µg/L) and 22% in previously chelated patients (2764-2011 µg/L)

"This large prospective study confirms that with appropriate dosing based on transfusion requirements, serum ferritin trends and safety markers, deferasirox over 1 year is effective in reducing iron burden…and has a well-defined and manageable safety profile.¹"

— N Gattermann et al